Teva Pharmaceutical Industries Limited (NYSE:TEVA) engages in the development and distribution of generic and other medicines, and biopharmaceutical products. The one-month return of Teva ...

Teva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

Ustekinumab products may decrease the protective ... Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel ...

Teva's Senior Vice President emphasized ... including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing ...

Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...

AMSTERDAM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- New research by Teva Pharmaceuticals Europe shows ... safety and efficacy as the innovator brand product, at offering cost-effective alternative ...

Teva Pharmaceutical Industries Ltd. (NYSE ... driven by our generic products and key innovative products. Medicine Pills (credit: INGIMAGE) Focusing on the rigorous execution of our Pivot to ...